Mostrar o rexistro simple do ítem
Predictive modeling of therapeutic response to chondroitin sulfate/glucosamine hydrochloride in knee osteoarthritis
dc.contributor.author | Blanco García, Francisco J | |
dc.contributor.author | Camacho Encina, María | |
dc.contributor.author | González-Rodríguez, Lucía | |
dc.contributor.author | Rego-Pérez, Ignacio | |
dc.contributor.author | Mateos, Jesús | |
dc.contributor.author | Fernández-Puente, Patricia | |
dc.contributor.author | Lourido Salas, Lucía María | |
dc.contributor.author | Rocha Loureda, Beatriz | |
dc.contributor.author | Picchi, Florencia | |
dc.contributor.author | Silva-Díaz, María T. | |
dc.contributor.author | Herrero, Marta | |
dc.contributor.author | Martínez, Helena | |
dc.contributor.author | Verges, Josep | |
dc.contributor.author | Ruiz-Romero, Cristina | |
dc.contributor.author | Calamia, Valentina | |
dc.date.accessioned | 2020-03-11T11:03:10Z | |
dc.date.available | 2020-03-11T11:03:10Z | |
dc.date.issued | 2019-08-24 | |
dc.identifier.citation | Blanco FJ, Camacho-Encina M, González-Rodríguez L, Rego-Pérez I, Mateos J, Fernández-Puente P, Lourido L, Rocha B, Picchi F, Silva-Díaz MT, Herrero M, Martínez H, Verges J, Ruiz-Romero C, Calamia V. Predictive modeling of therapeutic response to chondroitin sulfate/glucosamine hydrochloride in knee osteoarthritis. Ther Adv Chronic Dis. 2019 Aug 24;10:2040622319870013. | es_ES |
dc.identifier.issn | 2040-6223 | |
dc.identifier.uri | http://hdl.handle.net/2183/25158 | |
dc.description.abstract | [Abstract] Background: In the present study, we explored potential protein biomarkers useful to predict the therapeutic response of knee osteoarthritis (KOA) patients treated with pharmaceutical grade Chondroitin sulfate/Glucosamine hydrochloride (CS+GH; Droglican, Bioiberica), in order to optimize therapeutic outcomes. Methods: A shotgun proteomic analysis by iTRAQ labelling and liquid chromatography–mass spectrometry (LC-MS/MS) was performed using sera from 40 patients enrolled in the Multicentre Osteoarthritis interVEntion trial with Sysadoa (MOVES). The panel of proteins potentially useful to predict KOA patient’s response was clinically validated in the whole MOVES cohort at baseline (n = 506) using commercially available enzyme-linked immunosorbent assays kits. Logistic regression models and receiver-operating-characteristics (ROC) curves were used to analyze the contribution of these proteins to our prediction models of symptomatic drug response in KOA. Results: In the discovery phase of the study, a panel of six putative predictive biomarkers of response to CS+GH (APOA2, APOA4, APOH, ITIH1, C4BPa and ORM2) were identified by shotgun proteomics. Data are available via ProteomeXchange with identifier PXD012444. In the verification phase, the panel was verified in a larger set of KOA patients (n = 262). Finally, ITIH1 and ORM2 were qualified by a blind test in the whole MOVES cohort at baseline. The combination of these biomarkers with clinical variables predict the patients’ response to CS+GH with a specificity of 79.5% and a sensitivity of 77.1%. Conclusions: Combining clinical and analytical parameters, we identified one biomarker that could accurately predict KOA patients’ response to CS+GH treatment. Its use would allow an increase in response rates and safety for the patients suffering KOA. | es_ES |
dc.description.sponsorship | The author(s) disclosed receipt of the following financial support for the research, authorship, and publication of this article: MCE is supported by the Xunta de Galicia and the European Union [European Social Fund (ESF)] through a predoctoral fellowship (IN606A-2016/012). LGR is supported by an FPU grant from the Ministerio de Educación, Cultura y Deporte (Spain). LL and BR are supported by postdoctoral grants from the Xunta de Galicia (IN606B-2016/004 and IN606B-2016/004, respectively). IRP and CRR are supported by the Miguel Servet program contract from Fondo Investigación Sanitaria (Spain). This study was partially funded by Bioiberica SA, Barcelona, Spain. The sponsor provided serum samples free of charge and met some of the expenses that arose during the course of the study. This work was also funded by grants from Fondo Investigación Sanitaria-Spain (PI14/01707, PI16/02124, PI17/00404, DTS17/00200, CIBER-CB06/01/0040 and RETIC-RIER-RD16/0012/0002). The Proteomics Unit belongs to ProteoRed, PRB3- ISCIII (PT13/0001 and PT17/0019/0014). | es_ES |
dc.description.sponsorship | Xunta de Galicia; IN606A-2016/012 | es_ES |
dc.description.sponsorship | Xunta de Galicia; IN606B-2016/004 | es_ES |
dc.description.sponsorship | Xunta de Galicia; IN606B-2016/004 | es_ES |
dc.description.sponsorship | info:eu-repo/grantAgreement/MINECO/Programa Estatal de I+D+I Orientada a los Retos de la Sociedad/PI14%2F01707/ES/Validación de biomarcadores proteicos de artrosis mediante proteómica dirigida para el desarrollo de un método de diagnóstico in vitro | es_ES |
dc.description.sponsorship | info:eu-repo/grantAgreement/MINECO/Programa Estatal de I+D+I Orientada a los Retos de la Sociedad/PI16%2F02124/ES/Determinación de índices predictivos de diagnóstico y pronóstico de artrosis de rodilla mediante la validación de biomarcadores proteicos | es_ES |
dc.description.sponsorship | info:eu-repo/grantAgreement/ISCIII/Programa Estatal de Fomento de la Investigación Científica y Técnica de Excelencia/PI17%2F00404/ES/IDENTIFICACION Y VALIDACION DE BIOMARCADORES CIRCULANTES PREDICTIVOS DE RESPUESTA A ESTRATEGIAS DE TERAPIA BIOLOGICA EN PACIENTES CON ARTRITIS REUMATOIDE (BIO-RESTER) | |
dc.description.sponsorship | info:eu-repo/grantAgreement/ISCIII/Programa Estatal de Fomento de la Investigación Científica y Técnica de Excelencia/DTS17%2F00200/ES/DESARROLLO Y VALIDACION CLINICA DE UN KIT PARA EL DIAGNOSTICO PRECOZ DE LA ARTROSIS | |
dc.description.sponsorship | Instituto de Salud Carlos III; CB06/01/0040 | |
dc.description.sponsorship | info:eu-repo/grantAgreement/MINECO/Programa Estatal de I+D+I Orientada a los Retos de la Sociedad/RD16%2F0012%2F0002/ES/Red de Investigación en Inflamación y Enfermedades Reumáticas (RIER) | |
dc.description.sponsorship | info:eu-repo/grantAgreement/MINECO/Programa Estatal de I+D+I Orientada a los Retos de la Sociedad/PT13%2F0001%2F0012/ES/Plataforma de recursos biomoleculares y bioinformaticos | |
dc.description.sponsorship | Instituto de Salud Carlos III; PT17/0019/0014 | |
dc.language.iso | eng | es_ES |
dc.publisher | Sage | es_ES |
dc.relation.uri | https://doi.org/10.1177%2F2040622319870013 | es_ES |
dc.rights | Creative Commons Attribution-NonCommercial 4.0 International License (CC-BY-NC 4.0) | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/4.0/ | * |
dc.subject | Chondrotin sulfate/glucosamine hydrochloride | es_ES |
dc.subject | Knee osteoarthritis | es_ES |
dc.subject | Predictive biomarkers | es_ES |
dc.subject | Proteomics | es_ES |
dc.title | Predictive modeling of therapeutic response to chondroitin sulfate/glucosamine hydrochloride in knee osteoarthritis | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.rights.access | info:eu-repo/semantics/openAccess | es_ES |
UDC.journalTitle | Therapeutic Advances in Chronic Diseases | es_ES |
UDC.volume | 10 | es_ES |
UDC.startPage | 2040622319870013 | es_ES |
Ficheiros no ítem
Este ítem aparece na(s) seguinte(s) colección(s)
-
INIBIC- REUMA - Artigos [184]